AR053575A1 - Combinacion para la terapia de hiperplasia benigna de prostata - Google Patents

Combinacion para la terapia de hiperplasia benigna de prostata

Info

Publication number
AR053575A1
AR053575A1 ARP060101410A ARP060101410A AR053575A1 AR 053575 A1 AR053575 A1 AR 053575A1 AR P060101410 A ARP060101410 A AR P060101410A AR P060101410 A ARP060101410 A AR P060101410A AR 053575 A1 AR053575 A1 AR 053575A1
Authority
AR
Argentina
Prior art keywords
controlled release
release formulation
combination
inhibitor
benign hyperplasia
Prior art date
Application number
ARP060101410A
Other languages
English (en)
Original Assignee
Bayer Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag filed Critical Bayer Healthcare Ag
Publication of AR053575A1 publication Critical patent/AR053575A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Abstract

Un procedimiento novedoso para el tratamiento de síntomas en hiperplasia benigna de prostata. A este respecto se usan de forma simultánea: (1) un antagonista del adrenoreceptor alfa-1 en formulacion de liberacion controlada o un inhibidor de 5-alfa- reductasa y (2) un inhibidor de PDE 5 de GMPc en formulacion de liberacion controlada o un inhibidor de PDE 5 de GMPc con mayor tiempo de semivida. Reivindicacion 2: Forma farmacéutica segun la reivindicacion 1, que contiene una formulacion de liberacion controlada de tamsulosina, alfuzosina, doxazosina o terazosina así como una formulacion de liberacion controlada de vardenafilo o sildenafilo. Reivindicacion 3: Forma farmacéutica segun la reivindicacion 1, que contiene una formulacion de liberacion controlada de tamsulosina, alfuzosina, doxazosina o terazosina así como tadalafilo.
ARP060101410A 2005-04-13 2006-04-11 Combinacion para la terapia de hiperplasia benigna de prostata AR053575A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102005016981A DE102005016981A1 (de) 2005-04-13 2005-04-13 Kombination zur Therapie bei benigner Prostatahyperplasie

Publications (1)

Publication Number Publication Date
AR053575A1 true AR053575A1 (es) 2007-05-09

Family

ID=36608700

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060101410A AR053575A1 (es) 2005-04-13 2006-04-11 Combinacion para la terapia de hiperplasia benigna de prostata

Country Status (22)

Country Link
EP (1) EP1888075A1 (es)
JP (1) JP2008535877A (es)
KR (1) KR20080007252A (es)
CN (1) CN101193638A (es)
AR (1) AR053575A1 (es)
AU (1) AU2006233567A1 (es)
BR (1) BRPI0610634A2 (es)
CA (1) CA2605224A1 (es)
CR (1) CR9427A (es)
DE (1) DE102005016981A1 (es)
DO (1) DOP2006000074A (es)
GT (1) GT200600145A (es)
IL (1) IL186604A0 (es)
MA (1) MA29683B1 (es)
MX (1) MX2007012567A (es)
PE (1) PE20061338A1 (es)
RU (1) RU2007141518A (es)
SV (1) SV2008002477A (es)
TN (1) TNSN07385A1 (es)
TW (1) TW200716122A (es)
UY (1) UY29473A1 (es)
WO (1) WO2006108519A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6143746A (en) * 1994-01-21 2000-11-07 Icos Corporation Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
US20070093493A1 (en) * 2005-10-12 2007-04-26 Lilly Icos Llc Treatment of benign prostatic hypertrophy and lower urinary tract symptoms
US20080261995A1 (en) * 2005-12-21 2008-10-23 Pfizer Inc. Pharmaceutical Combination of a Pde-5 Inhibitor and a 5-Alpha Reductase Inhibitor
WO2008005039A1 (en) * 2006-07-07 2008-01-10 Teva Pharmaceutical Industries Ltd. Solid compositions comprising tadalafil and at least one carrier
DE102007028869A1 (de) 2007-06-22 2008-12-24 Ratiopharm Gmbh Verfahren zur Herstellung eines Arzneimittels enthaltend Tadalafil
NZ585923A (en) 2007-12-13 2012-09-28 Vanda Pharmaceuticals Inc Use of 4-[3-[4-(6-fluoro-1,2,-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methoxy-benzoic acid for treating a condition that is mediated by a 5-HT2A receptor
WO2009076663A1 (en) 2007-12-13 2009-06-18 Vanda Pharmaceuticals Inc. Method and composition for treating an alpha adrenoceptor-mediated condition
US8654746B2 (en) 2010-04-26 2014-02-18 Intel Corporation Method, apparatus and system for fast session transfer for multiple frequency band wireless communication
WO2013123965A1 (en) * 2012-02-20 2013-08-29 Synthon Bv A fixed dose pharmaceutical formulation
CN102727456B (zh) * 2012-07-03 2016-06-22 北京科信必成医药科技发展有限公司 药物口腔崩解片及其制备方法
CN105338970B (zh) * 2013-06-28 2019-07-09 韩美药品株式会社 包含他达拉非和坦洛新的药物胶囊复合制剂
DK3024474T3 (da) 2013-07-23 2022-03-28 Serenity Pharmaceuticals Llc Sammensætninger omfattende desmopressin i kombination med en beta-3-adrenoreceptor-agonist
KR101663238B1 (ko) * 2013-11-15 2016-10-14 한미약품 주식회사 타다라필 및 암로디핀을 포함하는 복합 고형 제제
CN106659690B (zh) * 2014-06-30 2020-08-18 韩美药品株式会社 包括含有活性成分的膜包衣层的复合制剂
WO2016003181A1 (ko) * 2014-06-30 2016-01-07 한미약품 주식회사 활성성분-함유 필름 코팅층을 포함하는 복합제제
WO2016003180A1 (ko) * 2014-06-30 2016-01-07 한미약품 주식회사 5-α-환원효소 억제제-함유 필름 코팅층을 포함하는 복합제제 및 그 제조방법
KR20170097045A (ko) * 2014-11-20 2017-08-25 알레간 인코포레이티드 알파-아드레날린성 수용체 길항제와 조합된 데스모프레신을 포함하는 방법 및 조성물
JP2019510071A (ja) * 2016-03-31 2019-04-11 ハンミ ファーマシューティカルズ カンパニー リミテッド 安定性及び溶出率が改善されたタダラフィル含有及びタムスロシン含有のカプセル複合製剤
KR101835506B1 (ko) * 2016-10-25 2018-03-07 주식회사 에스텍파마 두타스테리드와 타다라필을 함유하는 속효성 복합정제
CN108066347B (zh) * 2016-11-16 2021-02-02 深圳万和制药有限公司 包含坦索罗辛和度他雄胺的口腔崩解片药物组合物
KR101879133B1 (ko) * 2017-07-11 2018-07-17 (주)동구바이오제약 비뇨기 질환 예방 또는 치료용 제제 및 이의 제조방법
TR201715231A2 (tr) * 2017-10-09 2019-04-22 Montero Gida Sanayi Ve Ticaret Anonim Sirketi Dapokseti̇n ve fosfodi̇esteraz ti̇p-5 i̇nhi̇bi̇törü i̇çeren farmasöti̇k kombi̇nasyon

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050042177A1 (en) * 2003-07-23 2005-02-24 Elan Pharma International Ltd. Novel compositions of sildenafil free base

Also Published As

Publication number Publication date
AU2006233567A1 (en) 2006-10-19
DOP2006000074A (es) 2006-10-15
SV2008002477A (es) 2008-02-08
TNSN07385A1 (en) 2009-03-17
CR9427A (es) 2007-12-17
MA29683B1 (fr) 2008-08-01
UY29473A1 (es) 2006-11-30
CA2605224A1 (en) 2006-10-19
DE102005016981A1 (de) 2006-10-19
GT200600145A (es) 2007-04-10
JP2008535877A (ja) 2008-09-04
RU2007141518A (ru) 2009-05-20
KR20080007252A (ko) 2008-01-17
MX2007012567A (es) 2007-12-10
PE20061338A1 (es) 2007-01-28
IL186604A0 (en) 2008-01-20
EP1888075A1 (de) 2008-02-20
TW200716122A (en) 2007-05-01
WO2006108519A1 (de) 2006-10-19
CN101193638A (zh) 2008-06-04
BRPI0610634A2 (pt) 2010-07-13

Similar Documents

Publication Publication Date Title
AR053575A1 (es) Combinacion para la terapia de hiperplasia benigna de prostata
DOP2022000096A (es) Formas cristalinas de un inhibidor de tirosina quinasa de bruton
AR048819A1 (es) Metodos sinergicos y composiciones para el tratamiento del cancer
WO2015193740A3 (en) Therapeutic combinations of a btk inhibitor, a pi3k inhibitor and/or a jak-2 inhibitor
CO6612228A2 (es) Inhibidores de jak2 y su uso en el tratamiento de enfermedades mieloproliferativas y cancer
CL2008001743A1 (es) Uso de un compuesto derivado de quinazolina para tratar el cancer; uso del compuesto y de otro compuesto antineoplasico; compuestos derivados de quinazolina; y composicion farmaceutica que los comprende.
CL2008001364A1 (es) Uso de compuestos derivados de imidazol(1,2-b) piridazina y pirazolo(1,5-a) pirimidina inhibidores de tirosina quinasa pi-para tratar tumor benigno o maligno, entre otros; compuestos dereivados de imidazol(1,2-b)piridazina y pirazolo(1,5-a)pirimidina; composiciones farmaceuticas; y metodo de preparacion de compuestos.
ECSP066990A (es) Formulaciones con liberación controlada de principio activo que contienen vardenafilo
AR091876A1 (es) Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas
NO20071078L (no) Antivirale forbindelser
NO20081592L (no) Dipeptidylpeptidaseinhibitorer for behandling av diabetes
CL2011000710A1 (es) Combinacion farmaceutica que comprende un inhibidor especifico de smoothened y un inhibidor de cinasa pi3 especifico; y uso en el tratamiento de cancer.
CY1116878T1 (el) sGC ΔΙΕΓΕΡΤΕΣ Ή sGC ΕΝΕΡΓΟΠΟΙΗΤΕΣ ΜΟΝΟΙ ΚΑΙ ΣΕ ΣΥΝΔΥΑΣΜΟ ME PDE5 ΑΝΑΣΤΟΛΕΙΣ ΓΙΑ ΤΗΝ ΘΕΡΑΠΕΥΤΙΚΗ ΑΓΩΓΗ ΤΗΣ ΚΥΣΤΙΚΗΣ ΙΝΩΣΗΣ
CL2011000489A1 (es) Compuestos derivados de pirimido[5,4-d]pirimidina, los cuales actuan como inhibidores de tirosina-quinasas; y composiciones farmaceuticas que los comprenden, utiles en el tratamiento de enfermedades que se caracterizan por una proliferacion celular excesiva o anomala
MX2019003134A (es) Terapia de combinacion.
CO2017004517A2 (es) Inhibidores de las tirosina cinasas de bruton derivados de la 2, 3, 4, 9-tetrahidro-ih-carbazol-8- carboxamida y 9h-carbazol-l-carboxamida, composiciones que los comprenden y metodos de elaboration
NO20081973L (no) PDE inhibitorer og kombinasjoner derav i behandlingen av urologiske lidelser
CL2011000195A1 (es) Compuestos derivados de 5-alquinil-pirimidina, inhibidores de quinasas; composiciones farmaceuticas que comprenden a los compuestos; y uso de los compuestos en la preparacion de medicamentos para el tratamiento del cancer.
CR20130459A (es) DERIVADOS DE PIRIDINIL- Y PIRAZINIL-METILOXI-ARIL ÚTILES COMO INHIBIDORES DE TIROSINA CINASA DEL BAZO (Syk)
CL2007003251A1 (es) Compuestos derivados de 1h-pirazoles sustituidos, inhibidores de reacciones catalizadas por una quinasa; su procedimiento de preparacion; composicion farmaceutica; compuestos intermediarios; uso de los compuestos principales, utiles en el tratamiento del cancer.
UY33790A (es) Composiciones y métodos para tratar el cáncer usando un inhibidor de pi3k e inhibidor de mek.
PA8578001A1 (es) Combinaciones terapeuticas de inhibidores de quinasa de erb b y terapias antineoplasicas
CL2022000995A1 (es) Compuestos de 4-aminoisoindolina-1,3-diona sustituidos y segundos principios activos para uso combinado
CL2014000606A1 (es) Combinacion farmaceutica que comprende al compuesto 2-{2-[(2s)-2-metil-2,3-dihidro-1h-indol-1-il]-2-oxoetil}-6-(morfolin-4-il)pirimidin-4-(3h)-ona y al menos un inhibidor de la via de mapk; composicion farmaceutica; kit farmaceutico; su uso en el tratamiento del cancer.
AR052048A1 (es) Composiciones farmaceuticas para el tratamiento de la celulitis

Legal Events

Date Code Title Description
FB Suspension of granting procedure